LTF and amyloidosis: Briefly, AMPs are associated with the inhibition of Aβ oligomerization and fibrillization (e.g., cystatins), reduction of amyloid deposition (e.g., lactoferrin), and mitigation of amyloid-induced cell toxicity (e.g., α-defensin), which may be due to the direct interaction with Aβ peptides and/or modulation of inflammation to lessen amyloidosis.